Application value of new liver function scoring models in radiofrequency ablation for hepatocellular carcinoma

Chen MinQiang; Li WenTao; Liu XiaoGuang; Xu Hao; Chen NianPing

doi:10.3969/j.issn.1001-5256.2020.09.041

Volume 36 Issue 9

Sep. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(9): 2092-2096

PDF( 315 KB)

Application value of new liver function scoring models in radiofrequency ablation for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2020.09.041

Department of Hepatobiliary Surgery, The Affiliated Hospital of Guangdong Medical University

Published Date: 2020-09-20

Abstract

Abstract

Comprehensive scoring models are one of the main methods for liver function evaluation and an important part of the treatment strategy for hepatocellular carcinoma. This article summarizes the value and limitations of traditional scoring models( Child-Turcotte-Pugh score and Model for End-Stage Liver Disease score) and new scoring models( albumin-bilirubin score,platelet-albumin-bilirubin score,and albumin-indocyanine green score) in radiofrequency ablation for hepatocellular carcinoma and points out that the new scoring models,especially platelet-albumin-bilirubin score,are advantageous.
- hepatocellular carcinoma,
- catheter ablation,
- liver function score

FullText(HTML)

References(30)

References

[1] HO SY,LIU PH,HSU CY,et al. Prognostic performance of ten liver function models in patients with hepatocellular carcinoma undergoing radiofrequency ablation[J]. Sci Rep,2018,8(1):843.

[2] FANG KC,SU CW,CHIOU YY,et al. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation:A propensity score matching analysis[J]. Eur Radiol,2017,27(6):2600-2609.

[3] GIORGIO A,MEROLA MG,MONTESARCHIO L,et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis:Analysis of complications in a single centre over 20 years[J]. Br J Radiol,2017,90(1074):20160804.

[4] PARK JG,PARK SY,TAK WY,et al. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma:An analysis of 1,843 ablations in 1,211 patients in a single centre:Experience over 10 years[J]. Clin Radiol,2017,72(8):692. e9-692.e15.

[5] ZHANG L,GE NL,CHEN Y,et al. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma:10-year follow-up in Chinese patients[J]. Med Oncol,2015,32(3):77.

[6] FONSECA AZ,SAAD WA,RIBEIRO JR MA. Complications after radiofrequency ablation of 233 hepatic tumors[J]. Oncology,2015,89(6):332-336.

[7] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2019年版)[J]．临床肝胆病杂志，2020,36(2):277-292.

[8] LEE SK,SONG MJ,KIM SH,et al. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin(PALBI)and albumin-bilirubin(ALBI)grade:A nationwide cohort study[J]. PLo S One,2019,14(5):e0216173.

[9] LIU PH,HSU CY,HSIA CY,et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era[J]. J Gastroenterol Hepatol,2017,32(4):879-886.

[10] MALINCHOC M,KAMATH PS,GORDON FD,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology,2000,31(4):864-871.

[11] SANTAMBROGIO R,BRUNO S,KLUGER MD,et al. Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma[J]. Dig Liver Dis,2016,48(2):189-196.

[12] LEE S,RHIM H,KIM YS,et al. Post-ablation des-gammacarboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma[J]. Liver Int,2016,36(4):580-587.

[13] WANG Y,JIA JD. Evaluation of liver function and general condition before ablation and principles of medical treatment[J].Natl Med J China,2015,95(27):2160-2163.(in Chinese)王宇，贾继东．消融术前肝脏功能及全身情况评估与内科治疗原则[J]．中华医学杂志，2015,95(27):2160-2163.

[14] XIA F,LAI EC,LAU WY,et al. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis Brelated small hepatocellular carcinoma[J]. Ann Surg Oncol,2012,19(4):1284-1291.

[15] QADAN M,GARDEN OJ,CORVERA CU,et al. Management of postoperative hepatic failure[J]. J Am Coll Surg,2016,222(2):195-208.

[16] JOHNSON PJ,BERHANE S,KAGEBAYASHI C,et al. Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J]. J Clin Oncol,2015,33(6):550-558.

[17] HIRAOKA A,KUMADA T,KUDO M,et al. Albumin-Bilirubin(ALBI)grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology:A comparison with the liver damage and Child-Pugh classifications[J]. Liver Cancer,2017,6(3):204-215.

[18] NA SK,YIM SY,SUH SJ,et al. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma[J]. J Surg Oncol,2018,117(5):912-921.

[19] CHONG CC,CHAN AW,WONG J,et al. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma[J]. Surgeon,2018,16(3):163-170.

[20] KAO WY,SU CW,CHIOU YY,et al. Hepatocellular carcinoma:Nomograms based on the Albumin-Bilirubin grade to assess the outcomes of radiofrequency ablation[J]. Radiology,2017,285(2):670-680.

[21] CHEN PC,CHIU NC,SU CW,et al. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy[J]. J Chin Med Assoc,2019,82(1):2-10.

[22] OH IS,SINN DH,KANG TW,et al. Liver function assessment using Albumin-Bilirubin grade for patients with very earlystage hepatocellular carcinoma treated with radiofrequency ablation[J]. Dig Dis Sci,2017,62(11):3235-3242.

[23] CHAN AW,KUMADA T,TOYODA H,et al. Integration of albumin-bilirubin(ALBI)score into Barcelona Clinic Liver Cancer(BCLC)system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol,2016,31(7):1300-1306.

[24] CHAN AW,CHONG CC,MO FK,et al. Incorporating albuminbilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol,2017,32(1):221-228.

[25] KOKUDO T,HASEGAWA K,AMIKURA K,et al. Assessment of preoperative liver function in patients with hepatocellular carcinoma-the Albumin-Indocyanine Green Evaluation(ALICE)Grade[J]. PLo S One,2016,11(7):e0159530.

[26] MIYAZAKI Y,KOKUDO T,AMIKURA K,et al. Albumin-indocyanine green evaluation grading system predicts post-hepatectomy liver failure for biliary tract cancer[J]. Dig Surg,2019,36(1):13-19.

[27] RUSSOLILLO N,FORCHINO F,CONCI S,et al. Validation of the albumin-indocyanine green evaluation model in patients with resected hepatocellular carcinoma and comparison with the albumin-bilirubin score[J]. J Hepatobiliary Pancreat Sci,2019,26(1):51-57.

[28] JARUVONGVANICH V,SEMPOKUYA T,WONG L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?[J]. J Gastrointest Oncol,2018,9(4):750-761.

[29] SHIN J,YU JH,JIN YJ,et al. Effective therapeutic options for elderly patients with hepatocellular carcinoma:A nationwide cohort study[J]. Medicine(Baltimore),2019,98(30):e16150.

[30] TAKAMOTO T,SUGAWARA Y,HASHIMOTO T,et al. Evaluating the current surgical strategies for hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol,2016,10(3):341-357.

Relative Articles

[1]	Daqing LIU, Yan HUANG, Jianhe GAN. Value of serum creatinine-to-cystatin C ratio in assessing the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(2): 264-270. doi: 10.12449/JCH240208
[2]	Wenling LUO, Yu ZENG, Xuemei ZHANG, Yunjian SHENG. Influence of metabolism-related factors on the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(10): 1985-1991. doi: 10.12449/JCH241010
[3]	Xiaohua LIU, Shujuan YANG, Yushan LIU, Juan LI, Qiao ZHANG, Yamin WANG, Taotao YAN, Yuan YANG, Yingren ZHAO, Yingli HE. Value of peripheral blood lymphocyte count in evaluating the short－term prognosis of patients with acute－on－chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(10): 2383-2389. doi: 10.3969/j.issn.1001-5256.2023.10.016
[4]	Yan WANG, Ying XU, Wei SUN, Li CHEN, Jianhe GAN, Jing GU. Value of interleukin-6 combined with Model for End-Stage Liver Disease score in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(8): 1774-1779. doi: 10.3969/j.issn.1001-5256.2022.08.011
[5]	Shaoyu DONG, Changyu SUN, Fangfang QIAO, Xiao LIU, Jianying ZHANG. Value of age and D-dimer combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(11): 2478-2482. doi: 10.3969/j.issn.1001-5256.2022.11.008
[6]	Tingting DENG, Li LI, Ying GUAN, Xueyan LUO, Kun QIN, Min LIU. Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(10): 2346-2351. doi: 10.3969/j.issn.1001-5256.2022.10.028
[7]	Chenrui LIU, Yaping LI, Sen LUO, Dandan FENG, Fengping WU, Song ZHAI, Shuangsuo DANG. Influencing factors for the short-term prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(1): 56-62. doi: 10.3969/j.issn.1001-5256.2021.01.012
[8]	Dongqing ZHANG, Ruidan ZHENG, Minghua LIN, Wenjun WU, Shenglong LIN, Xiangmei WANG, Huaxi MA, Qin LI, Hanhui YE, Haibing GAO. Influencing factors for the 90-day prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2021.10.011
[9]	Xinyi GAO, Li CHEN, Jianhe GAN. Value of Model for End-Stage Liver Disease score combined with platelet-to-white blood cell ratio in predicting the prognosis of patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(5): 1070-1074. doi: 10.3969/j.issn.1001-5256.2021.05.019
[10]	Yang ShuJuan, Tian Zhen, He YingLi, Zhao YingRen, Zhang Jing, Lu: HengYi, Song HongBo. Predisposing factors for acute-on-chronic liver failure and their influence on prognosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 128-131. doi: 10.3969/j.issn.1001-5256.2020.01.028
[11]	Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(1): 123-127. doi: 10.3969/j.issn.1001-5256.2020.01.027
[12]	Li Chen, Tan JunYuan, Xu Xiang. Development and prognosis of acute-on-chronic liver failure in patients with acute deterioration of hepatitis B virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1960-1965. doi: 10.3969/j.issn.1001-5256.2020.09.010
[13]	Tong JingJing, Mu XiuYing, Xu Xiang, Chen Jing, Zhai XingRan, Wang Yu, Su HaiBin, Liu XiaoYan, Hu JinHua. Association between blood ammonia and 90-day prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1304-1307. doi: 10.3969/j.issn.1001-5256.2019.06.024
[14]	Wang JiaXin, Cheng Na, Xiang TianXin, Li ShuYue, Xiao JinPing, Wu XiaoPing. Establishment and evaluation of short-term prognostic model for hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2019.06.023
[15]	Wang Wei, Zhao RongRong, Yang XiaoFei, Huang ZhangXing, Lian JianQi, Wang JiuPing, Zhang Ye. Influence of Notch signaling pathway on interleukin-22 secreted by CD4~+T cells in patients with hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1315-1318. doi: 10.3969/j.issn.1001-5256.2016.07.020
[16]	Li Long, Wu ZhangHui, Wei Jia. Research progress in association between interleukin 28B gene polymorphism and hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1916-1920. doi: 10.3969/j.issn.1001-5256.2015.11.040
[17]	Lu Ying. Correlation of serum interleukin-33 with HBV DNA load and ALT level in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1853-1856. doi: 10.3969/j.issn.1001-5256.2015.11.020
[18]	Tan GuoLei, Sun Mei, Wang JianFang, Wu XuPing. Relationship between IL- 28B polymorphisms and susceptibility to hepatitis C among Han population in Jiangsu Province, China[J]. Journal of Clinical Hepatology, 2014, 30(6): 514-517. doi: 10.3969/j.issn.1001-5256.2014.06.009
[19]	Shi XiaoDong, Jiang Jing, Niu JunQi. Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 28-31.
[20]	Zuo WeiZe, Xu ChunMei, Shen LanChao. Changes in serum level of interleukin-32 and interleukin-6 in patients with chronic hepatitis B virus infection and its clinical significance[J]. Journal of Clinical Hepatology, 2011, 27(4): 408-410+413.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	李炎，孙永岑. 专科护士主导的O2O多学科管理在肝硬化代偿期患者中的应用. 临床护理杂志. 2024(05): 39-43 .
2.	郝志明，窦琴，包晓云. 基于PI3K/Akt信号通路探讨肝康片对四氯化碳致肝纤维化大鼠肝功能的保护机制. 现代消化及介入诊疗. 2020(02): 188-192 .
3.	朱豫萌，朱丹燕，张国强. 中西药合用治疗慢性乙型病毒性肝炎疗效观察. 实用中医药杂志. 2019(09): 1101-1103 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (566) PDF downloads(88)

Application value of new liver function scoring models in radiofrequency ablation for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2020.09.041